Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,275,810
  • Shares Outstanding, K 60,682
  • Annual Sales, $ 288,670 K
  • Annual Income, $ -521,070 K
  • EBIT $ -342 M
  • EBITDA $ -322 M
  • 60-Month Beta 0.67
  • Price/Sales 28.73
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 42.69% ( -3.25%)
  • Historical Volatility 36.57%
  • IV Percentile 32%
  • IV Rank 15.53%
  • IV High 118.25% on 04/17/24
  • IV Low 28.80% on 09/23/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 15
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 5,676
  • Open Int (30-Day) 8,449

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.46
  • Number of Estimates 8
  • High Estimate -0.35
  • Low Estimate -1.88
  • Prior Year -1.66
  • Growth Rate Est. (year over year) +12.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
126.74 +10.23%
on 12/10/24
141.48 -1.26%
on 12/17/24
+9.89 (+7.62%)
since 11/22/24
3-Month
118.05 +18.34%
on 11/15/24
149.67 -6.66%
on 09/30/24
-6.90 (-4.71%)
since 09/23/24
52-Week
111.09 +25.75%
on 09/12/24
161.00 -13.23%
on 02/26/24
+15.15 (+12.16%)
since 12/22/23

Most Recent Stories

More News
Ascendis Pharma A/S Announces U.S. Commercial Availability of YORVIPATH® for Hypoparathyroidism Treatment

Ascendis Pharma announces YORVIPATH's FDA approval and availability for treating adult hypoparathyroidism in the U.S.Quiver AI SummaryAscendis Pharma A/S has announced that its medication YORVIPATH® (palopegteriparatide),...

ASND : 139.70 (+2.43%)
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

ASND : 139.70 (+2.43%)
Ascendis Pharma Reports Positive Week 26 Results for TransCon hGH in Turner Syndrome Clinical Trial

The Phase 2 trial of TransCon hGH in Turner syndrome showed comparable safety and growth benefits to daily somatropin.Quiver AI SummaryAscendis Pharma announced positive results from the Week 26 analysis...

ASND : 139.70 (+2.43%)
New InsiGHTS Trial of TransConâ„¢ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

ASND : 139.70 (+2.43%)
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

ASND : 139.70 (+2.43%)
Ascendant Resources Announces Transformative Developments at Lagoa Salgada VMS Project, Portugal

Lagoa Salgada poised to become the next new mine on the Iberian Pyrite Belt

ASND.TO : 0.0500 (+11.11%)
ASND : 139.70 (+2.43%)
ASDRF : 0.0331 (-1.49%)
Can BioMarin Stock Live Up to Wall Street’s High Expectations?

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

ASND : 139.70 (+2.43%)
BMRN : 66.27 (+0.93%)
Ascendis Pharma Reports Third Quarter 2024 Financial Results

ASND : 139.70 (+2.43%)
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

ASND : 139.70 (+2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 146.44
2nd Resistance Point 143.45
1st Resistance Point 141.58
Last Price 139.70
1st Support Level 136.72
2nd Support Level 133.73
3rd Support Level 131.86

See More

52-Week High 161.00
Fibonacci 61.8% 141.93
Last Price 139.70
Fibonacci 50% 136.04
Fibonacci 38.2% 130.16
52-Week Low 111.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar